KR20130092972A - 인슐린-아연 복합체의 제조 방법 - Google Patents

인슐린-아연 복합체의 제조 방법 Download PDF

Info

Publication number
KR20130092972A
KR20130092972A KR1020127029547A KR20127029547A KR20130092972A KR 20130092972 A KR20130092972 A KR 20130092972A KR 1020127029547 A KR1020127029547 A KR 1020127029547A KR 20127029547 A KR20127029547 A KR 20127029547A KR 20130092972 A KR20130092972 A KR 20130092972A
Authority
KR
South Korea
Prior art keywords
insulin
cooh
chain
group
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127029547A
Other languages
English (en)
Korean (ko)
Inventor
렌 안드레슨
로사 레베카 에리체 한슨
퍼 제페슨
Original Assignee
노보 노르디스크 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노보 노르디스크 에이/에스 filed Critical 노보 노르디스크 에이/에스
Publication of KR20130092972A publication Critical patent/KR20130092972A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020127029547A 2010-05-10 2011-05-09 인슐린-아연 복합체의 제조 방법 Ceased KR20130092972A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10162368 2010-05-10
EP10162368.4 2010-05-10
US33349710P 2010-05-11 2010-05-11
US61/333,497 2010-05-11
PCT/EP2011/057388 WO2011141407A1 (en) 2010-05-10 2011-05-09 Process for the preparation of insulin-zinc complexes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020167023293A Division KR20160105979A (ko) 2010-05-10 2011-05-09 인슐린-아연 복합체의 제조 방법

Publications (1)

Publication Number Publication Date
KR20130092972A true KR20130092972A (ko) 2013-08-21

Family

ID=42732779

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020127029547A Ceased KR20130092972A (ko) 2010-05-10 2011-05-09 인슐린-아연 복합체의 제조 방법
KR1020167023293A Ceased KR20160105979A (ko) 2010-05-10 2011-05-09 인슐린-아연 복합체의 제조 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167023293A Ceased KR20160105979A (ko) 2010-05-10 2011-05-09 인슐린-아연 복합체의 제조 방법

Country Status (12)

Country Link
US (5) US20130143803A1 (enExample)
EP (1) EP2569002B1 (enExample)
JP (2) JP6249773B2 (enExample)
KR (2) KR20130092972A (enExample)
CN (2) CN107029212A (enExample)
AU (1) AU2011252127B2 (enExample)
BR (1) BR112012028766A2 (enExample)
CA (1) CA2795091A1 (enExample)
ES (1) ES2612468T3 (enExample)
MX (1) MX2012012943A (enExample)
RU (1) RU2572214C2 (enExample)
WO (1) WO2011141407A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1846446B1 (en) 2005-02-02 2013-06-26 Novo Nordisk A/S Insulin derivatives
PT1969004E (pt) 2005-12-28 2011-11-25 Novo Nordisk As Composições que compreendem uma insulina acilada e zinco e método para criar tais composições
ATE482977T1 (de) 2006-02-27 2010-10-15 Novo Nordisk As Insulinderivate
MX2008014061A (es) 2006-05-09 2008-11-14 Novo Nordisk As Derivado de insulina.
WO2007128815A1 (en) 2006-05-09 2007-11-15 Novo Nordisk A/S Insulin derivative
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
CN101932601B (zh) 2007-11-08 2016-08-03 诺沃-诺迪斯克有限公司 胰岛素衍生物
ES2607003T3 (es) 2008-10-30 2017-03-28 Novo Nordisk A/S Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyección inferior a la diaria
JP6049625B2 (ja) 2010-10-27 2016-12-21 ノヴォ ノルディスク アー／エス 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
EP2976096B1 (en) * 2013-03-20 2019-02-27 Novo Nordisk A/S Insulin dosing regimen
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
CN105636979B (zh) * 2013-10-07 2020-01-10 诺和诺德股份有限公司 胰岛素类似物的新衍生物
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
DK3006045T3 (en) 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
MX2020005916A (es) 2017-12-07 2020-10-19 Adocia Composiciones en forma de una solución acuosa inyectable que comprende amilina, un receptor agonista de amilina o un análogo de amilina y un copoliaminoácido.
WO2019110797A1 (fr) * 2017-12-07 2019-06-13 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
MX2020008129A (es) * 2018-02-01 2020-09-18 Jiangsu Hengrui Medicine Co Composicion farmaceutica que comprende un derivado acilado de un analogo de insulina humana y metodo de preparacion de la misma.
KR20210016400A (ko) 2018-05-24 2021-02-15 지앙수 헨그루이 메디슨 컴퍼니 리미티드 재조합 인간 인슐린 또는 그 유사체의 전구체를 제조하는 방법
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
BR112021011156A2 (pt) 2018-12-11 2021-10-26 Sanofi Conjugados de insulina
CN114096269B (zh) 2019-07-12 2024-06-11 诺和诺德股份有限公司 高浓度胰岛素制剂

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1212679B (de) * 1957-08-03 1966-03-17 Novo Terapeutisk Labor As Verfahren zur Herstellung von Insulinloesungen
GB1042194A (en) * 1962-04-30 1966-09-14 Olin Mathieson Insulin preparations
US3868358A (en) * 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
DK113585D0 (da) * 1985-03-12 1985-03-12 Novo Industri As Nye peptider
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US4764592A (en) * 1987-04-23 1988-08-16 Eli Lilly And Company Crystalline human proinsulin and process for its production
KR910700262A (ko) 1988-12-23 1991-03-14 안네 제케르 사람 인슐린 유사체
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
EP0792290B1 (en) * 1993-09-17 2001-08-29 Novo Nordisk A/S Acylated insulin
US7097845B2 (en) * 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
EP2264066A3 (en) * 2003-08-05 2011-07-27 Novo Nordisk A/S Novel insulin derivatives
WO2005012347A2 (en) 2003-08-05 2005-02-10 Novo Nordisk A/S Novel insulin derivatives
PT1969004E (pt) * 2005-12-28 2011-11-25 Novo Nordisk As Composições que compreendem uma insulina acilada e zinco e método para criar tais composições
US9034818B2 (en) * 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物

Also Published As

Publication number Publication date
BR112012028766A2 (pt) 2017-06-13
CN102883743A (zh) 2013-01-16
EP2569002B1 (en) 2016-10-26
US20150250857A1 (en) 2015-09-10
ES2612468T3 (es) 2017-05-17
AU2011252127A1 (en) 2012-11-01
US20210060132A1 (en) 2021-03-04
US20170165327A1 (en) 2017-06-15
KR20160105979A (ko) 2016-09-08
RU2012148821A (ru) 2014-06-20
EP2569002A1 (en) 2013-03-20
MX2012012943A (es) 2012-11-29
JP2013526501A (ja) 2013-06-24
US20130143803A1 (en) 2013-06-06
CA2795091A1 (en) 2011-11-17
CN107029212A (zh) 2017-08-11
US20240307503A1 (en) 2024-09-19
JP2017203042A (ja) 2017-11-16
RU2572214C2 (ru) 2015-12-27
AU2011252127B2 (en) 2014-02-20
JP6249773B2 (ja) 2017-12-20
WO2011141407A1 (en) 2011-11-17

Similar Documents

Publication Publication Date Title
JP6249773B2 (ja) インスリン−亜鉛錯体の調製方法
US9603904B2 (en) Treating diabetes melitus using insulin injections with less than daily injection frequency
ES2360505T3 (es) Preparados de insulina libre de zinc o con bajo contenido en cinc con estabilidad mejorada.
JP6111475B2 (ja) ヒトインスリン又はその類似体もしくは誘導体を含む安定な水性組成物
US20130261051A1 (en) Treating Diabetes Melitus Using Insulin Injections Administered With Varying Injection Intervals
US10596229B2 (en) Method of treating diabetes mellitus by administration, at specifically defined intervals, of a derivative of a naturally occurring insulin or insulin analogue, the derivative having a prolonged profile of action
AU2013368990A1 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20121112

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
A302 Request for accelerated examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150121

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20150121

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150520

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20150918

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20150520

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20150918

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20150713

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20150121

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20151123

Patent event code: PE09021S01D

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20160527

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20151123

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20151019

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20150918

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20150713

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20150520

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20150121

PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20160825